...
首页> 外文期刊>Applied Spectroscopy: Society for Applied Spectroscopy >High-Throughput Raman Spectroscopy Screening of Excipients for the Stabilization of Amorphous Drugs
【24h】

High-Throughput Raman Spectroscopy Screening of Excipients for the Stabilization of Amorphous Drugs

机译:高通量拉曼光谱筛选稳定无定形药物的辅料

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Low aqueous solubility of active pharmaceutical ingredients (APIs) is an enduring problem in pharmaceutical development, and it is becoming increasingly prevalent among new drug candidates. It is estimated that about 40% of drugs in the development pipeline and approximately 60% of the drugs coming directly from discovery suffer from poor aqueous solubility and slow dissolution, thereby reducing their bioavailability and efficacy and thus preventing their commercialization. It is well known that utilizing the amorphous form of a drug can be a useful approach to improve the dissolution rate and solubility of poorly water-soluble APIs. Amorphous compounds are thermodynamically unstable, but they can be stabilized by combining them with a carrier polymer (excipient) to form a solid dispersion. High-throughput Raman spectroscopy was used in this study to identify excipients that promote formation and stabilization of the amorphous drug form in solid dispersions. Four model APIs were used as poorly soluble drug candidates: ketoprofen, danazol, griseofulvin, and probucol. The Raman signals of excipients were generally negligible, and therefore Raman bands from the drugs were used with minimal spectral pre-processing. By comparing Raman spectra collected from the APIs in the crystalline and molten state, appropriate spectral features and regions were identified for the development of semi-quantitative methods to determine the amorphous content for each API. It is demonstrated that methods based on peak intensity ratio, peak width, peak distance, and classical least squares can all be effective methods for the screening of excipients. Interesting excipient-dependent phase transformation behavior was also observed for probucol.
机译:活性药物成分(API)的低水溶性是药物开发中的一个持久问题,并且在新药物候选物中变得越来越普遍。据估计,开发管线中约40%的药物和直接来自发现的约60%的药物具有不良的水溶性和缓慢的溶解性,从而降低了它们的生物利用度和功效,从而阻止了它们的商业化。众所周知,利用药物的无定形形式可以是改善水溶性差的API的溶解速率和溶解性的有用方法。非晶态化合物在热力学上是不稳定的,但可以通过将它们与载体聚合物(赋形剂)结合以形成固体分散体来使其稳定。在这项研究中,高通量拉曼光谱用于鉴定能促进固体分散体中无定形药物形式的形成和稳定的赋形剂。四种模型API被用作难溶性药物候选物:酮洛芬,达那唑,灰黄霉素和普罗布考。赋形剂的拉曼信号通常可以忽略不计,因此使用药物的拉曼谱带进行的光谱预处理最少。通过比较在结晶态和熔融态下从API收集的拉曼光谱,可以确定适当的光谱特征和区域,以开发半定量方法以确定每种API的非晶含量。结果表明,基于峰强度比,峰宽,峰距离和经典最小二乘法的方法都可以作为筛选赋形剂的有效方法。普罗布考还观察到有趣的赋形剂依赖性相变行为。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号